FI3236960T3 - Fluralaneeri käytettäväksi demodikoosin hoidossa - Google Patents

Fluralaneeri käytettäväksi demodikoosin hoidossa Download PDF

Info

Publication number
FI3236960T3
FI3236960T3 FIEP15817303.9T FI15817303T FI3236960T3 FI 3236960 T3 FI3236960 T3 FI 3236960T3 FI 15817303 T FI15817303 T FI 15817303T FI 3236960 T3 FI3236960 T3 FI 3236960T3
Authority
FI
Finland
Prior art keywords
compound
mammal
fluralaner
treatment
demodicosis
Prior art date
Application number
FIEP15817303.9T
Other languages
English (en)
Finnish (fi)
Inventor
Heike Williams
Anja Heckeroth
Janina Tänzler
Régis Frenais
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Application granted granted Critical
Publication of FI3236960T3 publication Critical patent/FI3236960T3/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/14Ectoparasiticides, e.g. scabicides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
FIEP15817303.9T 2014-12-22 2015-12-21 Fluralaneeri käytettäväksi demodikoosin hoidossa FI3236960T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14199562 2014-12-22
PCT/EP2015/080744 WO2016102437A1 (en) 2014-12-22 2015-12-21 Use of isoxazoline compounds for treating demodicosis

Publications (1)

Publication Number Publication Date
FI3236960T3 true FI3236960T3 (fi) 2025-04-05

Family

ID=52146273

Family Applications (2)

Application Number Title Priority Date Filing Date
FIEP15817303.9T FI3236960T3 (fi) 2014-12-22 2015-12-21 Fluralaneeri käytettäväksi demodikoosin hoidossa
FIEP21213190.8T FI4008329T3 (fi) 2014-12-22 2015-12-21 Isoksatsoliiniyhdisteitä käytettäväksi hoidettaessa demodikoosia

Family Applications After (1)

Application Number Title Priority Date Filing Date
FIEP21213190.8T FI4008329T3 (fi) 2014-12-22 2015-12-21 Isoksatsoliiniyhdisteitä käytettäväksi hoidettaessa demodikoosia

Country Status (14)

Country Link
US (3) US20170348286A1 (enExample)
EP (3) EP3236960B1 (enExample)
JP (1) JP6706262B2 (enExample)
CN (2) CN114681453A (enExample)
AU (3) AU2015371175B2 (enExample)
BR (1) BR112017013286A2 (enExample)
CA (1) CA2971296A1 (enExample)
DK (2) DK3236960T3 (enExample)
ES (2) ES3037078T3 (enExample)
FI (2) FI3236960T3 (enExample)
PL (2) PL3236960T3 (enExample)
PT (2) PT4008329T (enExample)
RU (1) RU2709198C2 (enExample)
WO (1) WO2016102437A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016022066A1 (en) 2014-08-04 2016-02-11 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
PL3236960T3 (pl) 2014-12-22 2025-07-07 Intervet International B.V. Fluralaner do zastosowania w leczeniu demodekozy
WO2018039508A1 (en) * 2016-08-25 2018-03-01 Merial, Inc. Method for reducing unwanted effects in parasiticidal treatments
CN107501199A (zh) * 2017-08-16 2017-12-22 南京农业大学 氟雷拉纳单体化合物的提取和纯化方法
KR20250057155A (ko) * 2017-12-15 2025-04-28 타르서스 파마수티칼스, 아이엔씨. 안검염을 치료하기 위한 이속사졸린 구충제 제제 및 방법
US11880349B2 (en) 2019-04-30 2024-01-23 Salesforce, Inc. System or method to query or search a metadata driven distributed ledger or blockchain
WO2022020585A1 (en) 2020-07-24 2022-01-27 Elanco Us Inc. Process for making an isoxazoline compound and intermediate thereof
CN115785017B (zh) * 2022-12-06 2023-12-08 海利尔药业集团股份有限公司 一种取代的苯酰胺异噁唑啉衍生物或其作为农药可接受的盐、组合物及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2067863C1 (ru) * 1994-05-25 1996-10-20 Казанский государственный технологический университет Акарицидный состав для лечения чесотки домашних животных
RS53639B1 (sr) 2004-03-05 2015-04-30 Nissan Chemical Industries Ltd. Izoksazolinom supstituisano benzamidno jedinjenje i sredstvo za kontrolu štetnih organizama
DE102004053964A1 (de) * 2004-11-09 2006-05-11 Bayer Healthcare Ag Mittel gegen Demodikose
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
TWI430995B (zh) 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
HUE037127T2 (hu) 2007-06-27 2018-08-28 Du Pont Állati károkozó irtására szolgáló eljárás
TWI556741B (zh) * 2007-08-17 2016-11-11 英特威特國際股份有限公司 異唑啉組成物及其作為抗寄生蟲藥上的應用
TWI411395B (zh) 2007-12-24 2013-10-11 Syngenta Participations Ag 殺蟲化合物
US8377942B2 (en) 2008-12-18 2013-02-19 Novartis Ag Isoxazolines derivatives and their use as pesticide
RU2518462C2 (ru) * 2008-12-19 2014-06-10 Новартис Аг Органические соединения
EP2658541B2 (en) 2010-12-27 2025-12-17 Intervet International B.V. Topical localized isoxazoline formulation comprising glycofurol
CN103260621B (zh) 2010-12-27 2016-08-24 英特维特国际股份有限公司 外用局部异噁唑啉制剂
ES2585555T3 (es) 2011-03-10 2016-10-06 Zoetis Services Llc Derivados espirocíclicos de isoxazolina como agentes antiparasitarios
SG11201400558YA (en) 2011-09-12 2014-04-28 Merial Ltd Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof
SMT201900083T1 (it) 2012-02-06 2019-02-28 Merial Inc Composizioni veterinarie orali parassiticide comprendenti principi attivi che agiscono per via sistematica, loro metodi e loro usi
AU2013245011B2 (en) 2012-04-04 2017-11-23 Intervet International B.V. Solid oral pharmaceutical compositions for isoxazoline compounds
WO2014090918A1 (en) * 2012-12-13 2014-06-19 Novartis Ag Process for the enantiomeric enrichment of diaryloxazoline derivatives
CN110327468B (zh) 2013-12-20 2023-04-28 英特维特国际股份有限公司 异噁唑啉组合物及其在预防或治疗动物的寄生虫侵袭中的用途
PL3236960T3 (pl) 2014-12-22 2025-07-07 Intervet International B.V. Fluralaner do zastosowania w leczeniu demodekozy

Also Published As

Publication number Publication date
EP3236960A1 (en) 2017-11-01
ES3018234T3 (en) 2025-05-14
AU2023219972B2 (en) 2025-05-29
EP4008329A1 (en) 2022-06-08
CA2971296A1 (en) 2016-06-30
RU2017126029A (ru) 2019-01-24
EP4599830A2 (en) 2025-08-13
EP4008329B1 (en) 2025-06-11
BR112017013286A2 (pt) 2018-03-06
DK3236960T3 (da) 2025-03-31
CN114681453A (zh) 2022-07-01
FI4008329T3 (fi) 2025-08-22
CN106999475B (zh) 2022-10-25
JP6706262B2 (ja) 2020-06-03
EP3236960B1 (en) 2025-01-29
DK4008329T3 (da) 2025-08-18
AU2023219972A1 (en) 2023-09-14
PL3236960T3 (pl) 2025-07-07
PL4008329T3 (pl) 2025-11-17
AU2015371175A1 (en) 2017-06-15
JP2017538767A (ja) 2017-12-28
WO2016102437A1 (en) 2016-06-30
ES3037078T3 (en) 2025-09-26
US20180318265A1 (en) 2018-11-08
AU2015371175B2 (en) 2021-03-04
EP4599830A3 (en) 2025-11-19
RU2017126029A3 (enExample) 2019-06-20
RU2709198C2 (ru) 2019-12-17
US20170348286A1 (en) 2017-12-07
CN106999475A (zh) 2017-08-01
PT3236960T (pt) 2025-04-08
US10799483B2 (en) 2020-10-13
US20200405692A1 (en) 2020-12-31
PT4008329T (pt) 2025-07-30
AU2021203686A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
FI3236960T3 (fi) Fluralaneeri käytettäväksi demodikoosin hoidossa
NL301342I2 (nl) Elafibranor, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
FIC20240025I1 (fi) Momelotinibi, mukaanlukien momelotinibidihydrokloridimonohydraatti
NL301260I2 (nl) Gefapixant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
WO2016011390A8 (en) Irak4 inhibiting agents
EP3423653A4 (en) LOCKING ARRANGEMENT WITH STOP LOCKING
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
AR098274A1 (es) Inhibidor de grelina o-acil transferasa
AR103680A1 (es) Inhibidores selectivos de bace1
MX373716B (es) Compuesto de pirazol-amida y sus usos farmaceuticos.
AR098870A1 (es) Formas polimorficas de una sal de clorhidrato de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolin-4(3h)-ona
EA201690894A1 (ru) Феноксиэтилы
LT3533787T (lt) Piridono junginys kaip c-met inhibitorius
MX2016009794A (es) Derivado de sulfonamida heterociclico y medicina que comprende el mismo.
HUE056922T2 (hu) 2-szubsztituált amino-naft[1,2-D]imidazol-5-on vegyületek vagy azok gyógyszerészetileg elfogadható sói
TN2017000097A1 (en) Heterocyclic compound
EA201592268A1 (ru) Дигидропиридиноновые ингибиторы mgat2
WO2016089886A3 (en) Methods for treating dry eye disease by administering an il-6r antagonist
MA43873A (fr) Dspositif d'injection
DK3129392T3 (da) Triterpenoider med hiv-modningsinhiberende aktivitet, substitueret i position 3 af en ikke-aromatisk ring som bærer en haloalkylsubstituent
AR095097A1 (es) Compuestos de fenoxietoxi
LT3202766T (lt) Izoksazolo darinys, kaip mutuotos izocitrato dehidrogenazės 1 inhibitorius
EP2953470A4 (en) 2,6,7-SUBSTITUTED PURINS AS HDM2 INHIBITORS
EA201892449A1 (ru) Конденсированные гетероциклические соединения
MX2017006110A (es) Carboxamidas de quinolina para usarse en el tratamiento de leucemia.